A medical science liaison's job isn't to sell a drug, it's to make sure the clinical team in front of them understands exactly what it does, what the data actually shows, and where it realistically fits next to everything else on the shelf. Apremilast (Otezla) is a good drug to practice that on: an oral option for plaque psoriasis and psoriatic arthritis that occupies a specific, well-defined niche rather than competing head-on with biologics.
The Mechanism, in the Level of Detail an MSL Would Actually Use
Apremilast is a phosphodiesterase-4 (PDE4) inhibitor. PDE4 is the enzyme that normally breaks down cyclic AMP (cAMP) inside inflammatory cells. By inhibiting PDE4, apremilast raises intracellular cAMP levels, which shifts the cytokine balance toward less inflammation: downregulating pro-inflammatory mediators like TNF-α, IL-23, and IL-17, while upregulating the anti-inflammatory cytokine IL-10. That's a meaningfully different mechanism from the biologics covered in our biologics overview, which each target a single cytokine or receptor directly. Apremilast works upstream and more broadly across the inflammatory cascade, which is the mechanistic reason behind both its efficacy ceiling and its side effect profile.
What the Trial Data Actually Showed
Apremilast's pivotal Phase 3 program for plaque psoriasis, the ESTEEM trials, and for psoriatic arthritis, the PALACE trials, are the data an MSL would actually walk through. In ESTEEM, roughly a third of patients achieved PASI-75 (a 75% improvement in psoriasis severity) at week 16, against a mid-single-digit response on placebo, a real effect, but well below what most IL-17 or IL-23 biologics achieve in head-to-head terms. In the PALACE program, roughly a third of patients achieved ACR20 (a standard joint-response measure) at week 16 for psoriatic arthritis, again a real but moderate effect size. The honest clinical framing: apremilast works, but it's not positioned to compete with biologics on raw potency, and that's not a flaw in the data, it's the point of where the drug is meant to sit.
Where It Fits in the Treatment Ladder
Apremilast's competitive position in the psoriasis treatment ladder is defined by trade-offs against biologics, not head-to-head potency. It's oral rather than injectable, which matters to needle-averse patients or those who simply prefer a pill. It doesn't require the baseline tuberculosis and hepatitis screening, or the ongoing infection-risk monitoring, that most biologics call for, since it isn't broadly immunosuppressive in the same way. And it carries none of the boxed warning language around serious infection risk that shapes so much biologic counseling.
The trade-off is tolerability, not just efficacy: gastrointestinal upset, diarrhea, and some weight loss are apremilast's most common side effects, and they're dose-related enough that gradual titration is standard practice specifically to manage them. That combination, oral, monitoring-light, moderate efficacy, GI-driven tolerability considerations, is what an MSL would frame as apremilast's identity: a genuine middle-tier option between topicals and biologics, best suited to patients who want to avoid injections or immunosuppression and whose disease severity doesn't demand a biologic's ceiling.
The Question an MSL Gets Asked Most
"Why would I choose this over a biologic?" The honest answer isn't that apremilast is more effective, it isn't. It's that a meaningful subset of patients value the combination of oral dosing, no injection-site or infusion logistics, and a monitoring burden closer to a routine oral medication than an immunosuppressant. For those patients, and for prescribers managing patients who aren't candidates for biologics, apremilast's moderate efficacy is a reasonable trade against a substantially simpler treatment experience.
This is an educational overview and does not constitute medical or pharmaceutical advice. Treatment selection should always follow individualized clinical assessment and current prescribing information.